1h Free Analyst Time
The Cancer Biopsy Market grew from USD 29.84 billion in 2023 to USD 33.48 billion in 2024. It is expected to continue growing at a CAGR of 12.28%, reaching USD 67.14 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Cancer biopsy is a critical medical procedure for diagnosing cancer, involving the removal of tissue or cells for examination. The necessity of cancer biopsies lies in their ability to provide definitive diagnosis, guiding treatment plans and evaluating the extent or stage of cancer. Applications include traditional methods like surgical, needle, and endoscopic biopsies, alongside advanced techniques such as liquid biopsies, which offer less invasive diagnostic options. End-users primarily comprise hospitals, cancer research centers, and diagnostic laboratories.
The market for cancer biopsies is influenced by rising cancer prevalence, technological advancements in diagnostic procedures, and increasing patient awareness. The growing preference for minimally invasive diagnostics and the development of personalized medicine are significant growth factors. The integration of artificial intelligence and machine learning to enhance biopsy accuracy represents a critical potential opportunity. Companies can capitalize on this by investing in research and development to improve biopsy technologies and techniques that reduce patient discomfort and enhance test precision.
However, the market faces limitations and challenges, such as regulatory hurdles, high costs associated with advanced biopsy procedures, and potential risks like infection and bleeding. Moreover, the availability of alternative diagnostic methods, such as imaging, can sometimes limit the reliance on biopsies. Research and innovation areas ripe for exploration include the development of non-invasive biopsy techniques, improving accuracy in cancer detection, and real-time monitoring for treatment effectiveness.
Given the evolving landscape of oncology diagnostics, there are tremendous opportunities for market players to invest in improving data integration and interpretation tools, thereby enhancing the reliability and efficacy of cancer biopsy procedures. Businesses can also explore collaborations with healthcare providers and research institutions to innovate and streamline biopsy processes, addressing cost and accessibility issues. Overall, the market's nature is highly dynamic, driven by technological advancements and a continual push toward personalized cancer care, requiring ongoing innovation and adaptability from industry stakeholders.
Understanding Market Dynamics in the Cancer Biopsy Market
The Cancer Biopsy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.- Market Drivers
- Increasing preference for non-invasive procedures
- Emerging significance of cancer biopsies and tissue sectioning
- Growing adoption of liquid cancer biopsies
- Market Restraints
- Low sensitivity and specificity of cancer biopsies
- Market Opportunities
- Technological advancements in cancer biopsy devices
- Increasing R&D activities for novel cancer treatments
- Market Challenges
- Stringent regulatory requirements and unclear reimbursement scenarios
Exploring Porter’s Five Forces for the Cancer Biopsy Market
Porter’s Five Forces framework further strengthens the insights of the Cancer Biopsy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.Applying PESTLE Analysis to the Cancer Biopsy Market
External macro-environmental factors deeply influence the performance of the Cancer Biopsy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.Analyzing Market Share in the Cancer Biopsy Market
The Cancer Biopsy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.Evaluating Vendor Success with the FPNV Positioning Matrix in the Cancer Biopsy Market
The Cancer Biopsy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.Strategic Recommendations for Success in the Cancer Biopsy Market
The Cancer Biopsy Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.Key Company Profiles
The report delves into recent significant developments in the Cancer Biopsy Market, highlighting leading vendors and their innovative profiles. These include Agena Bioscience, Inc., Agilent Technologies Inc., ANGLE PLC, Becton, Dickinson and Company, BIOCEPT, Inc., Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., GRAIL, Inc., Guardant Health, HelioHealth, Hologic, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., MDx Health, Myriad Genetics, Inc., Natera, Inc., OncoCyte Corp, Personalis Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., and Trovagene, Inc.Market Segmentation & Coverage
This research report categorizes the Cancer Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:- Product
- Instruments
- Kits & Consumables
- Services
- Type
- Liquid Biopsies
- Tissue Biopsies
- Needle Biopsies
- Core Needle Biopsy
- Fine Needle Aspiration
- Surgical Biopsies
- Needle Biopsies
- Indication
- Blood Cancers
- Breast Cancer
- Cervical Cancers
- Colorectal Cancer
- Kidney Cancers
- Liver Cancers
- Lung Cancers
- Ovarian Cancers
- Pancreatic Cancers
- Prostate Cancers
- Skin Cancers
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report provides a detailed overview of the market, exploring several key areas:
- Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
- Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
- Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
- Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
- Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.
Additionally, the report addresses key questions to assist stakeholders in making informed decisions:
- What is the current size of the market, and how is it expected to grow?
- Which products, segments, and regions present the most attractive investment opportunities?
- What are the prevailing technology trends and regulatory factors influencing the market?
- How do top vendors rank regarding market share and competitive positioning?
- What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Cancer Biopsy Market, by Product
7. Cancer Biopsy Market, by Type
8. Cancer Biopsy Market, by Indication
9. Americas Cancer Biopsy Market
10. Asia-Pacific Cancer Biopsy Market
11. Europe, Middle East & Africa Cancer Biopsy Market
12. Competitive Landscape
LIST OF FIGURES
LIST OF TABLES
Companies Mentioned
The leading players in the Cancer Biopsy market, which are profiled in this report, include:- Agena Bioscience, Inc.
- Agilent Technologies Inc.
- ANGLE PLC
- Becton, Dickinson and Company
- BIOCEPT, Inc.
- Danaher Corporation
- Epigenomics AG
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd.
- Freenome Holdings, Inc.
- GRAIL, Inc.
- Guardant Health
- HelioHealth
- Hologic, Inc.
- Illumina, Inc.
- Laboratory Corporation of America Holdings
- Lucence Health Inc.
- MDx Health
- Myriad Genetics, Inc.
- Natera, Inc.
- OncoCyte Corp
- Personalis Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific, Inc.
- Trovagene, Inc
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 196 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 33.48 Billion |
| Forecasted Market Value ( USD | $ 67.14 Billion |
| Compound Annual Growth Rate | 12.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
